This publication was withdrawn on
Withdrawn as this product received a marketing authorisation from the European Commission.
- Medicines and Healthcare products Regulatory Agency
- 15 March 2016
- Last updated:
- 23 August 2016, see all updates
EAMS scientific opinion given to pembrolizumab for metastatic non-small cell lung cancer (NSCLC), including the public assessment report.
PDF, 93.1KB, 3 pages
PDF, 101KB, 6 pages
PDF, 167KB, 14 pages
PDF, 88.9KB, 3 pages
This positive scientific opinion was issued to MSD Ltd for pembrolizumab for the treatment of metastatic non-small cell lung cancer (NSCLC).
The scientific opinion includes:
- a public assessment report
- a treatment protocol:
- for healthcare professionals
- for patients
- on the pharmacovigilance system
Information and details regarding patient access
For new patients wishing to access EAMS medicines in England, trusts must submit an application form to firstname.lastname@example.org to register the patient with NHS England. The form itself can be requested from the same dedicated EAMS email address. Plans are underway to introduce a web based application form as soon as possible. Trusts will be informed when this is available.
For information about access in Northern Ireland, contact Mark Timoney, Chief Pharmaceutical Officer at Mark.Timoney@dhsspsni.gsi.gov.uk and Joe Magee, Secondary Care Directorate at Joe.Magee@dhsspsni.gov.uk.
For information about access in Wales, contact the Welsh Government Department of Health and Social Services by emailing Andrew Evans, Interim Chief Pharmaceutical Officer at Andrew.Evans@wales.gsi.gov.uk and Karen Eveleigh, Head of Pharmacy and Prescribing policy at Karen.Eveleigh@wales.gsi.gov.uk.
Published: 15 March 2016
Updated: 23 August 2016
- Updating public assessment report.
- Updated documents.
- Removed "RCC" from first attachment title.
- First published.